MedTrace Logo

Is the Rate of Early Mobilisation in Hip Fracture Patients Using Alfentanil Better Than Standard Opioid Analgesia?

NCT06212622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-12-06

No results posted yet for this study

Summary

Hip fracture injuries are linked with increased morbidity, frailty, and mortality risk. Studies have shown that in hip fracture surgery, early mobilisation confers better pain control, 30-day complication and mortality rates and could reduce in hospital length of stay.

Though early mobilisation may provide numerous post operative benefits, there are barriers to achieving this reliably and effectively. One such difficulty is pain.

In the Royal Infirmary of Edinburgh (RIE) like many boards across Scotland, oral oxycodone has been routinely used as analgesia to help with post operative pain, in patients who have undergone orthopaedic trauma injuries. However, this analgesic modality is utilised to help with general post operative pain, rather than targeted abolition of pain prior to physiotherapy.

Alfentanil is a relatively new medication which has a very rapid onset of action and short half life. Alfentanil may prove to be a superior form of analgesia for the purpose of encouraging early mobilisation after hip fracture surgery. This study could provide robust evidence for regular use of alfentanil prior to physiotherapy in early post operative hip fracture surgery patients.

Conditions

  • Hip Injuries
  • Hip Fractures
  • Pain
  • Post Operative Pain
  • Early Ambulation

Interventions

DRUG

Alfentanil

Subcutaneous injection

DRUG

Oxycodone

Oral solution

Sponsors & Collaborators

  • NHS Lothian

    lead OTHER_GOV

Principal Investigators

  • Nicholas Clement, MBBS, MD, PhD, FRCS (T&O) · NHS Lothian

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2024-06-18
Completion
2024-07-18
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212622 on ClinicalTrials.gov